Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

With FDA approval of an investigational device exemption, J&J’s soft tissue robot moves a step closer to challenging ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

The alliance positions GE Healthcare to distribute Radnet software designed to help mammography centers view images, ...

CFO Joel Grade told investors Friday that Baxter expects an approximately $200 million hit to sales in the fourth quarter ...

Donald Trump’s election victory comes weeks after the FDA named a new leader for the medical device center and as the ...

The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.

CEO Bernd Montag said the company is well positioned for a “U.S. versus China situation” that could arise when Donald Trump ...